Results From the IQ-CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 4, 2015, Pages 326-335

  Darpo, B ^a,b   Benson, C ^c   Dota, C ^d   Ferber, G ^e   Garnett, C ^f   Green, C L ^g   Jarugula, V ^h   Johannesen, L ^i,j   Keirns, J ^k   Krudys, K ⁱ   Liu, J ⁱ   Ortemann Renon, C ^l   Riley, S ^m   Sarapa, N ⁿ   Smith, B ^b   Stoltz, R R ^o   Zhou, M ^b   Stockbridge, N ⁱ  

^a DANDERYD HOSPITAL   (Sweden)

^b ICARDIAC TECHNOLOGIES INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e Statistik Georg Ferber GmbH   (Switzerland)

^f CERTARA   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^l SANOFI   (France)

^m PFIZER INC   (United States)

ⁿ BAYER CORPORATION   (United States)

^o D/b/a Covance GFI Research   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

ADULT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; LONG QT SYNDROME; MALE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADULT; CARDIOVASCULAR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; LINEAR MODELS; LONG QT SYNDROME; MALE; PROSPECTIVE STUDIES;

EID: 84929132718     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.60     Document Type: Note

References (46)

1. Barbey, J.T., Lazzara, R. & Zipes, D.P. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J. Cardiovasc. Pharmacol. Ther. 7, 65–76 (2002).
2. Honig, P.K., Wortham, D.C., Zamani, K., Conner, D.P., Mullin, J.C. & Cantilena, L.R. Terfenadine-ketoconazole interaction. Pharmacoki-netic and electrocardiographic consequences. JAMA 269, 1513– 1518 (1993).
3. Shah, R.R. The significance of QT interval in drug development. Br. J. Clin. Pharmacol. 54, 188–202 (2002).
4. Shah, R.R. Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam. Clin. Pharmacol. 16, 119–124 (2002).
5. ICH Harmonized Tripartite Guideline E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs . Accessed November 2014.
6. Darpo, B., Nebout, T. & Sager, P.T. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Require-ments for Registration of Pharmaceuticals for Human Use E14 guide-line. J. Clin. Pharmacol. 46, 498–507 (2006).
7. ICH E14 Questions & Answers . Accessed November 2014.
8. Bouvy, J.C., Koopmanschap, M.A., Shah, R.R. & Schellekens, H. The cost-effectiveness of drug regulation: the example of thorough QT/ QTc studies. Clin. Pharmacol. Ther. 91, 281–288 (2012).
9. Darpo, B., Garnett, C. Early QT assessment — how can our confidence in the data be improved? Br. J. Clin. Pharmacol. 76, 642–648 (2012).
10. Rohatagi, S., Carrothers, T.J., Kuwabara-Wagg, J. & Khariton, T. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs. J. Clin. Pharma-col. 49, 1284–1296 (2009).
11. Shah, R.R. & Morganroth, J. Early investigation of QTc liability: the role of multiple ascending dose (MAD) study. Drug Saf. 35, 695–709 (2012).
12. Zhang, J. & Machado, S.G. Statistical issues including design and sample size calculation in thorough QT/QTc studies. J. Biopharm. Stat. 18, 451–467 (2008).
13. Garnett, C.E. Value of evaluation concentration: QTc relationship in regulatory decision making. Presentation at ASCPT 2012 Annual meeting. Workshop: Evaluation of concentration: QTc relationship in early clinical development: Is a thorough QT study necessary? (2012).
14. Garnett, C.E. et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J. Clin. Pharmacol. 48, 13–18 (2008).
15. Tornoe, C.W., Garnett, C.E., Wang, Y., Florian, J., Li, M. & Gobburu, J.V. Creation of a knowledge management system for QT analyses. J. Clin. Pharmacol. 51, 1035–1042 (2011).
16. International Consortium for Innovation and Quality in Pharmaceutical Development . Accessed November 2014.
17. Cardiac Safety Research Consortium . Accessed November 2014.
18. Asenapine (Saphris). QT-IRT consult to NDA 22,117 . Accessed November 2014.
19. Citalopram (Celexa). FDA Drug Safety Communication: Revised rec-ommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses . Accessed November 2014.
20. Dolasetron (Anzamet). US label . Accessed November 2014.
21. Ondansetron (Zofran). Drug Safety Communication-QT prolongation. Juen 2012 . Accessed November 2014.
22. Ranolazine (Ranexa). US label . Accessed November 2014.
23. Sertindole. Advisory Committee briefing material for NDA 20-644, Psychopharmacologic Drugs Advisory Committee March 27, 2009 . Accessed November 2014.
24. Vandetanib. (Caprelsa) Clinical pharmacology review April 2011 . Accessed November 2014.
25. Qualaquin (quinine sulphate). Clinical pharmacology and biopharma-ceutics review(s) . Accessed November 2014.
26. Qualaquin (quinine sulphate). US label . Accessed November 2014.
27. Tsong, Y., Shen, M., Zhong, J. & Zhang, J. Statistical issues of QT prolongation assessment based on linear concentration modeling. J. Bio-pharm. Stat. 18, 564–584 (2008).
28. Wang, Y. & Garnett, C. Response to letter to the editor: statistical issues of QT prolongation assessment based on linear concentration modeling by Yi Tsong et al. J. Biopharm. Stat. 20, 689–692 (2010).
29. Shin, J.G. et al. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br. J. Clin. Pharmacol. 63, 206–215 (2007).
30. Vandetanib. (Caprelsa) US label October 2012 . Accessed November 2014.
31. Tikosyn (dofetilide). US label . Accessed November 2014.
32. Bedaquiline. Anti-infective Drugs Advisory committee meeting November 28, 2012. FDA Briefing document . Accessed November 2014.
33. Malik, M., Hnatkova, K., Ford, J. & Madge, D. Near-thorough QT study as part of a first-in-man study. J. Clin. Pharmacol. 48, 1146–1157 (2008).
34. Westerberg, G. et al. Safety, pharmacokinetics, pharmacogenomics and QT concentration effect modelling of the SirT1 inhibitor selisistat in healthy volunteers. Br.J.Clin.Pharmacol. (2014); epub ahead of print.
35. Ferber, G., Zhou, M. & Darpo, B. Detection of QTc effects in small studies-implications for replacing the thorough QT study. Ann. Nonin-vas. Electrocardiol. (2014); epub ahead of print.
36. Darpo, B. et al. The IQ-CSRC prospective clinical phase 1 study: “Can early QT assessment using exposure response analysis replace the thorough QT study?” Ann. Noninvas. Electrocardiol. 19, 70–81 (2014).
37. Kligfield, P. & Green, C.L. The Cardiac Safety Research Consortium ECG database. J. Electrocardiol. 45, 690–692 (2012).
38. Kligfield, P. et al. The Cardiac Safety Research Consortium electrocar-diogram warehouse: thorough QT database specifications and princi-ples of use for algorithm development and testing. Am. Heart J. 160, 1023–1028 (2010).
39. Zofran (ondansetron hydrochloride). US label . Accessed November 2014.
40. Anzemet (dolasetron mesylate). US label . Accessed November 2014.
41. Avelox (moxifloxacin hydrochloride). US label . Accessed November 2014.
42. Florian, J.A., Tornoe, C.W., Brundage, R., Parekh, A. & Garnett, C.E. Population pharmacokinetic and concentration–QTc models for moxi-floxacin: pooled analysis of 20 thorough QT studies. J. Clin. Pharma-col. 51, 1152–1162 (2011).
43. Hulhoven, R., Rosillon, D., Letiexhe, M., Meeus, M.A., Daoust, A. & Stockis, A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur. J. Clin. Phar-macol. 63, 1011–1017 (2007).
44. Xyzal (levocetirizine dihydrochloride). US label . Accessed November 2014.
45. Darpo, B. et al. Improving the precision of QT measurements. Cardiol. J. 18, 401–410 (2011).
46. Davison AC, Hinkley DV. Bootstrap methods and their application (Cambridge University Press, Cambridge, UK, 1997).